Figure 1.

Impact of PMP on ILD progression. Longitudinal changes in (a) forced vital capacity (percent predicted) and (b) diffusing capacity for carbon monoxide (percent predicted). Groups based on clinical improvement (“Improved”) or lack thereof (“Not Improved”). Data points are representative of PFTs performed immediately prior to PMP (BL) and rough intervals (6 and 9 months before PMP and 3, 6, and 9 months afterward). *p < 0.05 improved vs not improved group.

BL, baseline; ILD, interstitial lung disease; PMP, pulsed methylprednisolone sodium succinate.